Back HCV Treatment

HCV Treatment

AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b

A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.

alt

Read more:

Achillion's ACH-3102 + Sofosbuvir for 6 Weeks Shows 100% Cure Rate

Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.

alt

Read more:

AbbVie's Viekirax + Exviera "3D" Hepatitis C Regimen Approved in Europe

The European Commission last week approved AbbVie's interferon-free Viekirax plus Exviera combination regimen -- formerly known as "3D" -- for the treatment of genotype 1 chronic hepatitis C. This approval includes people with compensated liver cirrhosis, liver transplant recipients, HIV/HCV coinfected patients, and people on opioid substitution therapy for drug addiction. The commission also approved Viekirax plus ribavirin for HCV genotype 4.

alt

Read more:

AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.

alt

Read more:

Sofosbuvir/Ledipasvir + Third Drug Cures Most HCV Patients in 6 Weeks

A short and well-tolerated regimen of sofosbuvir, ledipasvir, and a third drug -- either GS-9669 or GS-9451 -- taken for as little as 6 weeks can cure a majority of previously untreated people with genotype 1 chronic hepatitis C, including those with traditional predictors of poor response, according to study results published in the January 12 advance edition of The Lancet.

alt

Read more: